

EARLY WARNING REPORT
National Instrument 62-103

This report is being filed pursuant to Section 5.2(2) of Multilateral Instrument 62 104.

The following information is filed pursuant to the provisions listed above under applicable securities legislation:

(a) Name and Address of the Reporting Issuer:

Medcolcanna Organics Inc. (“**Medcolcanna**” or the “**Company**”)
c/o EnerNext Counsel
Suite 800, 400 5th Avenue SW
Calgary, AB T2P 0L6

(b) Designation of Securities of the Reporting Issuer to which this Report relates:

Common shares in the capital of the Company (“**Common Shares**”).

(c) Name and Address of the Offeror:

Felipe de la Vega (the “**Offeror**”)
Cra 49b, #93-62
Bogota, Colombia

(d) Date of the Transaction giving rise to the Report

April 17, 2020

(e) Designation and number or principal amount of securities and the offeror's securityholding percentage in the class of securities of which the offeror acquired ownership or control in the transaction of occurrence giving rise to the obligation to file the news release, and whether it was ownership or control that was acquired in those circumstances:

The Offeror, a current insider of Medcolcanna by virtue of being an officer and director of the Company through his holdings personally as well as through shares held by his various holding companies as well as holding companies of his spouse and various immediate family members, announces that on April 17, 2020 he acquired all of the issued and outstanding shares of a company called Peregrine International Holdings (“**Peregrine**”) from an arm’s length seller by way of a private agreement. Peregrine holds a total of 1,990,000 Common Shares. Prior to completion of the issuance, the Offeror owned or exercised control over a total of 8,983,00 Common Shares. Following the acquisitions described above, the Offeror holds or exercises control or direction over a total of 10,973,000 Common Shares, representing approximately 12.14% of the issued and outstanding 90,350,667 Common Shares on an undiluted basis and approximately 9.91% of the issued and outstanding 124,359,363 Common Shares on a fully diluted basis (assuming exercise of all of the issued and outstanding 7,875,000 stock options, all 22,943,400 of the issued and outstanding common share purchase warrants and all 2,126,864 compensation options of the Company, plus the 1,063,432 Common Shares

issuable on the exercise of the warrants issued pursuant to said compensation options).

- (f) Designation and number or principal amount of securities and the offeror's securityholding percentage in the class of securities immediately after the transaction or occurrence giving rise to obligation to file the new release:**

See above under paragraph (e).

- (g) Designation and number or principal amount of securities and the percentage of outstanding securities of the class of securities referred to in paragraph (c) over which:**

- (i) the offeror, either alone or together with any joint actors, has ownership and control,**

See above under paragraph (e).

- (ii) the offeror, either alone or together with any joint actors, has ownership but control is held by other persons or companies other than the offeror or any joint actor, and**

Not applicable.

- (iii) the offeror, either alone or together with any joint actors, has exclusive or shared control but does not have ownership**

See above under paragraph (e).

- (e) Name of the market in which the transaction or occurrence that gave rise to the news release took place:**

Common Shares were purchased by way of a private agreement with an arm's length party and not through the facilities of any stock exchange.

- (e.1) Value, in Canadian dollars, of any consideration offered per security if the offeror acquired ownership of a security in the transaction or occurrence that gave rise to the obligation to file a news release:**

Offeror purchased all of the issued and outstanding shares of Peregrine for total gross proceeds of \$159,200 on April 17, 2020, representing an effective purchase price of \$0.08 per Common Share.

- (f) Purpose of the offeror and any joint actors in effecting the transaction or occurrence that gave rise to the news release, including any future intention to acquire ownership of, or control over, additional securities of the reporting issuer:**

The Offeror has acquired the securities for investment purposes and from time to time the Offeror may: (i) acquire additional securities of the Company, (ii) dispose of some or all of the existing or additional securities he holds or may hold or (iii) may continue to hold his current position. All such transactions will be reported on SEDI as the Offeror is currently an insider of the Company.

- (g) The general nature and the material terms of any agreement, other than lending arrangements, with respect to securities of the reporting issuer entered into by the offeror, or any joint actor, and the issuer of the securities or any other entity in connection with the transaction or occurrence giving rise to the news release, including agreements with respect to the acquisition, holding, disposition or voting of any of the securities:**

The Offeror entered into a verbal agreement for the purchase of all of the issued and outstanding shares of Peregrine with the owner of said company, being Nicolas Rubio, such agreement being effective April 17, 2020 (the “**Sale Agreement**”).

- (h) The names of any joint actors in connection with the disclosure required hereby:**

Not applicable.

- (i) In the case of a transaction or occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, the nature and value of the consideration paid by the offeror:**

Pursuant to the Sale Agreement, the Offeror paid a total of \$159,200 for all of the issued and outstanding shares in the capital of Peregrine.

- (j) If applicable, a description of any change in any material fact set out in a previous report by the entity under the early warning requirements or Part 4 in respect of the reporting issuer's securities:**

Not applicable.

- (k) If applicable, a description of the exemption from the formal bid requirements of applicable securities legislation being relied on by the offeror and the facts supporting that reliance:**

Not applicable.

The undersigned, as the Offeror, certify to the best of my knowledge, information and belief, that the statements made in this report are true and complete in every respect.

DATED at Bogota, Colombia as of the 21st day of April, 2020.

(signed) “Felipe de la Vega”

Felipe de la Vega